FDA grants priority review to Roche’s risdiplam for spinal muscular atrophy
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) and granted Priority Revie...



